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BMD at the femoral neck remained stable in both groups.Differential effects of growth hormone therapy in malnour-
Phagocytic activity of PMNLs increased significantly after threeished hemodialysis patients.
months of therapy with rhGH, whereas other parameters ofBackground. Malnutrition is common in chronic hemodialy-
PMNL function were not affected by GH. QoL was slightlysis patients and is associated with increased morbidity and mor-
improved in the GH treated group, but decreased markedlytality. Several factors such as metabolic acidosis, hyperparathy-
roidism, and insulin as well as growth hormone (GH) resistance in the placebo group.
may lead to enhanced protein catabolism. Recombinant human Conclusions. Three months of treatment with rhGH in mal-
growth hormone (rhGH) has been proposed as treatment of nourished patients on chronic hemodialysis causes a significant
malnutrition because of its anabolic effects. increase in IGF-I levels without significant changes in nutri-
Methods. In the present placebo-controlled, double blind tional and anthropometric parameters. In contrast, bone turn-
study, the effects of three months of rhGH therapy on nutri- over was enhanced with an initial decrease in BMD at the
tional and anthropometric parameters, on bone metabolism and lumbar spine, and phagocytic activity of PMNLs was increased.
bone mineral density (BMD), as well as on polymorphonuclear
leukocyte (PMNL) function and quality of life (QoL) were
evaluated in 19 malnourished hemodialysis patients (10 females Up to 70% of patients with chronic renal failure (CRF)
and 9 males) with a mean age of 59.3 13.4 years. RhGH (0.125
on hemodialysis suffer from malnutrition, one of the mainIU/kg) was given three times a week during the first four weeks
causes for their increased morbidity and mortality [1–6].and 0.25 IU/kg thereafter three times a week after each dialysis
session. Protein requirements often are increased in these patients,
Results. Insulin-like growth factor I (IGF-I) concentration but protein intake as well as protein synthesis are usually
rose significantly from 169.2  95.6 ng/mL to 262.9  144.4 reduced. Besides uremic toxicity, infections, psychosocialng/mL (p 0.01) in the group receiving rhGH. Albumin, pre-
factors and amino acid abnormalities, metabolic acidosisalbumin, transferrin, cholesterol, high-density lipoprotein (HDL)
cholesterol, cholinesterase, predialytic creatinine, and blood urea and endocrine abnormalities such as insulin resistance,
nitrogen showed no significant changes during the three months hyperparathyroidism, and growth hormone insensitivity
in both groups. Total body fat (%TBF) was slightly reduced enhance protein catabolism [7]. Increasing the dialysis
after three months (P  NS) in the patients receiving GH,
dose is one way to counteract these effects [8, 9]. In addi-whereas lean body mass (LBM) remained stable during ther-
tion, the administration of erythropoietin and the correc-apy. Procollagen I carboxy terminal peptide (PICP), a marker
of bone formation, increased significantly after three months tion of metabolic acidosis as well as intradialytic parenteral
from 250.1  112.6 to 478.5  235.2 g/L (P  0.01) in the nutrition (IPDN) have been shown to affect nutritional
GH-treated patients, whereas parameters of bone resorption and anthropometric parameters favorably [10–13].like telopeptide ICTP showed only a slight increase (50.3 
Patients with CRF on hemodialysis are resistant to the18.5 vs. 70.0  39.5 g/L, P  NS). BMD at the lumbar spine
actions of growth hormone (GH), insulin, and insulin-decreased significantly after three months in the treatment
group (0.8  0.17 vs. 0.77  0.16 g/cm2, P  0.01), whereas like growth factor I (IGF-I). Chronic metabolic acidosis,
inflammation, high concentrations of IGF-binding pro-
teins (IGFBPs), and therefore decreased bioavailabilityKey words: chronic renal failure, protein catabolism, bone turnover,
erythropoietin, metabolic acidosis, nutrition and dialysis. of IGF-I as well as reduced nutrient intake are the main
factors that might induce resistance to GH and IGF-I
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mineral density [20–22], only supraphysiological doses The study was prospective, randomized, double blind,
and placebo controlled (GH/placebo). The patients re-of GH and IGF-I induced a net decrease in total urea
nitrogen appearance in CRF patients [23–25]. Also, two ceived either recombinant GH (Genotropin R by Phar-
macia, Stockholm, Sweden) or placebo, which was sup-recently published studies demonstrated improvements
in anthropometric measurements, a decrease in predia- plied in identical cartridges for reconstitution with 1 mL
of water for injection with 3 mg of m-cresol. The rhGHlytic BUN levels, and an increase in serum albumin con-
centrations [26, 27]. dose was 0.125 IU/kg (40.5 g/kg) three times a week
during the first four weeks and 0.25 IU/kg (81 g/kg)The aim of the present study was to extend the hitherto
described observations of the effects of supraphysiological thereafter three times a week after each dialysis session.
In five of these patients, the dose had to be reducedrhGH doses in malnourished patients on chronic hemo-
dialysis with low IGF-I concentrations. These low IGF-I temporarily (1 week) by 50% because of adverse events.
Adverse events. Five patients developed a shunt throm-levels may indicate profound GH resistance as well as
reduced nutrient intakes. In addition to nutritional and bosis (3 patients receiving GH and 2 placebo). Six pa-
tients (5 patients receiving GH, 1 placebo) suffered fromanthropometric parameters, parameters of bone metab-
olism and bone mineral density (BMD), function of poly- arthralgias, and one patient receiving GH suffered from
newly developed headache. One patient who receivedmorphonuclear leukocytes, and quality of life (QoL) were
determined in a double blind, placebo-controlled, three- placebo died because of cardiovascular failure after one
month.month trial.
Biochemical, immunological, and anthropometric mea-
surements were performed in all subjects after the long
METHODS
dialysis-free period. Blood was drawn before and after the
Patients first dialysis of the week and again before the next dialysis
for urea determinations used to calculate urea kineticsNineteen malnourished patients (10 females and 9
males) with a mean age of 59.3  13.4 years on chronic (URR, PCR, Kt/V). Blood hemoglobin, blood glucose,
and serum biochemistries were analyzed by routine meth-hemodialysis entered this study after informed consent
was given. Patients had to be on chronic hemodialysis for ods. Serum C reactive protein (CRP) was measured by
using an immunonephelometric method (Tina-quant;at least six months. Patients fulfilling at least three out of
the four following criteria were included into the study: Bo¨hringer Mannheim, Mannheim, Germany). Albumin,
prealbumin, cholesterol, cholinesterase, protein, and trans-serum cholesterol and transferrin levels 200 mg/dL, se-
rum albumin concentrations41 g/L, and a body weight ferrin were determined by nephelometry (Nephelometer
BNA II; Behring Diagnostics, Marburg, Germany).of 80% of the optimal body weight. The protocol was
approved by the Human Ethics Committee of the Uni- Insulin-like growth factor I (IGF-I) was quantified by
a radioimmunoassay (RIA). Serum samples were ex-versity of Vienna. Eighteen patients finished the three-
month study. One patient (receiving placebo) died be- tracted by acid-ethanol method and diluted 1:20 prior
to determination. IGF-I rabbit antiserum was providedcause of cardiovascular failure after one month. Chronic
hemodialysis was performed three times weekly in all by the Hormone Distribution Program of NIDDK (Be-
thesda, MD, USA) and was used at a final dilution ofpatients using bicarbonate and biocompatible high (N 
10) or low-flux dialyzers (N  9), the duration was four 1:5000. The international reference preparation rhIGF-I
87/518 was from NIBSC (UK) and was used as standard.hours in most patients and was not changed during the
observation period. The tracer, prepared by iodination of recombinant IGF-I
and purified by HPLC, was from Amersham (Little Chal-Chronic renal failure was due to various etiologies in-
cluding polycystic kidney disease (N 1), chronic glomer- font, Buckinghamshire, UK). The detection limit of the
assay was 0.1 ng/tube. The intraassay coefficient of varia-ulonephritis (N  10), chronic pyelonephritis (N  4),
diabetic and/or hypertensive nephropathy and nephro- tion was 11.8% at 153 ng/mL, and the interassay coeffi-
cient of variation at 182 ng/mL was 9.4%. The RIA forangiosclerosis (N  4). Two of the patients were type I
diabetics requiring insulin. One patient was a type II IGFBP-3 (Miadiagnostik, Germany) utilized a specific
high polyclonal rabbit antibody. The tracer was prepareddiabetic. No patient had a history of a malignoma. Ten
patients had a history of cardiovascular disease. by direct radioiodination of pure IGFBP-3 and standards
refer to a stable derivate of IGFBP-3 with a molecular
Study design and treatment schedule weight of 30.5 kD. Serum was considerably diluted be-
fore analysis, but no extraction step was required. TheThe hypothesis to be tested by this study was to exam-
ine whether rhGH therapy in pharmacological doses im- sensitivity of the assay was 0.006 ng/mL.
Serum levels of intact parathyroid hormone (PTH)proves nutritional and anthropometric parameters or has
some impact on bone metabolism or granulocyte func- (Nichols Institute Diagnostics, San Juan Capistrano, CA,
USA) and serum osteocalcin (OC; CIS International,tion in hemodialysis patients.
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Table 1. Baseline characteristics of 19 patients on chronic hemodialysisGif sur Yvette, France) were measured by commercially
available RIAs. The intra-assay and interassay coeffi- GH group Placebo group P value
cient of variance (CV) were 7.5 and 6.8%, respectively, Sex male/female 3/6 6/4
Age years 54.214.3 65.111.4 0.36for intact PTH, and 3.8% and 5.2%, respectively, for
Hemoglobin g/dL 8.72.0 9.72.1 0.27serum osteocalcin. Serum concentrations of carboxyter-
PCR 0.820.14 0.750.11 0.19
minal propeptide of type I procollagen (PICP), n-termi- URR 0.710.08 0.660.04 0.17
Kt/V 1.40.31 1.240.30 0.50nal propeptide of type III procollagen (PIIINP) as well
as the telopeptide ICTP, were measured by commercially Abbreviations are: GH, growth hormone; PCR, protein catabolic rate; URR,
urea reduction ratio; Kt/V, dialysis dose.available RIA (Orion Diagnostica, Espoo, Finland). The
intra-assay CVs for PICP, PIIINP, and ICTP were 2.7,
2.5, and 2.8%, respectively. The interassay CVs were 6.6,
chest, thoracal-midaxillary, suprailiacal, paraumbilical,3.2, and 4.1%, respectively. An ELISA (Osteometer,
subscapular, triceps, front thigh (suprapatellar), bicepsBioTech, Herlev, Denmark) was performed to deter-
and popliteal [34]. Skinfolds were measured to the near-mine the serum Crosslaps.
est 0.2 mm, as the mean of three readings by the same
Bone densitometry investigator to eliminate the intertester variability. Mea-
surements were performed after hemodialysis. TotalX-ray films of the lumbar and thoracic spine and the
body fat (TBF) was calculated from the formula of Allenhip were obtained to exclude the possibility of spine frac-
et al [35]. The lean body mass (LBM) was derived bytures or severe osteoarthritis. BMD was measured using
subtracting TBF from body mass.dual-energy x-ray absorptiometry (DEXA) on a QDR
2000 TM device (Hologic R, Waltham, MA, USA). Sites
Quality of lifeof measurements were the lumbar spine (L1 to L4) and
the left femoral neck. The in vivo precision of DEXA Health-related quality of life (QoL) was measured
was 0.71% for the lumbar spine and 1.0% for the femoral using the self-rating questionnaire the Nottingham
neck. Health Profile (NHP I), where patients had to answer 38
questions concerning problems with emotional reaction,
Preparation of PMNLs sleep, energy, pain, physical mobility, and social life,
Polymorphonuclear leukocytes (PMNLs) were pre- [36, 37], and the AGHDA, which is a self-administered
pared from 10 mL heparinized (10 U/mL Liquemin; Roche, questionnaire designed specially to evaluate quality of
Basle, Switzerland) whole blood as described by Harbeck life in adults with GHD. This questionnaire consists of
et al [28]. Leukocyte-rich plasma was obtained using a 25 unidimensional items measuring the quality of life
Ficoll-Hypaque gradient and was layered on a Percoll aspects that are affected by GHD [38, 39]. Responses
gradient. This was centrifuged at 500  g for 25 minutes are of the yes/no type. High scores reflect a bad QoL
at room temperature. PMNLs were harvested in the su- in both questionnaires and improvements in QoL are
pernatant and then washed twice with Hank’s buffered reflected by a decrease in the scores.
saline (HBSS) with Ca2 and Mg2. Viability was tested
with trypan blue and was always greater than 90%. Statistical methods
Phagocytosis. Phagocytosis and intracellular killing of
The statistical analysis was performed using SAS soft-opsonized Escherichia coli cells were performed as de-
ware (version 6.09E). We employed the GLM procedurescribed by Moiola [29].
(to take into account the possible unbalanced data) forDetermination of PMNL (Ca2). Measurements of
detecting deviations in the course of time using the num-resting and stimulated (Ca2) of PMNLs were performed
ber of the patient and the time as class variables, butusing the fluorescent indicator Fura 2/AM (Sigma, Mu-
specifying the number of the patient as a random effectnich, Germany) as described previously [30, 31].
(that is, considering joint observations). We used Tukey’sDetermination of PMNL glucose uptake. Glucose up-
studentized range test (HSD) on the means of the maintake was determined as described by McCall et al [32].
effects (that is, time) to locate the points in time where
Anthropometric measurements significant deviations occur. Variables of interest were
described by their means and standard deviations (SD)Height was measured to the nearest 0.5 cm and body
and differences were considered significant with P 0.05.mass to the nearest 0.1 kg. The body mass index was
calculated as weight in kg divided by height in m2; body
surface area was computed from the equation of DuBois
RESULTSand DuBois [33]. Body composition assessment was de-
Patient characteristics are shown in Table 1. Baselinetermined by skinfold thickness measurement using a Hol-
tain caliper at 10 sites: cheek (temporal), chin, pectoral- nutritional and anthropometric parameters as well as
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Table 2. Nutritional parameters in 19 patients on
chronic hemodialysis
Variable Group 0 months P value 3 months
Albumin g/L GH 38.54.2 0.44 39.26.1
Placebo 39.93.7 42.35.7
Prealbumin mg/dL GH 26.57.6 0.74 26.711.1
Placebo 27.78.0 32.05.7
Transferrin mg/dL GH 172.938.6 0.97 19057.8
Placebo 173.430 17437.8
Cholesterol mg/dL GH 165.332.1 0.23 158.633.9
Placebo 188.239.4 180.222
HDL-cholesterol GH 46.411.7 0.58 4313.1
mg/dL Placebo 5118.6 49.117.6
Choline sterase GH 2.90.9 0.18 3.20.7
U/L Placebo 3.61.1 3.70.9
Predialytic GH 8.82.0 0.36 8.91.7
creatinine mg/dL Placebo 9.72.1 9.02.0
Predialytic BUN GH 58.619 0.37 64.514
mg/dL Placebo 6717.5 7420
Abbreviations are: BUN, blood urea nitrogen; GH, growth hormone; HDL,
high-density lipoprotein.
Table 3. Anthropometric parameters in 19 patients
on chronic hemodialysis
Group 0 months P value 3 months
Fig. 1. Mean insulin-like growth factor-I and (IGF-I) and IGF-binding
protein-3 (IGFBP-3) levels during three months treatment with growthWeight kg GH 60.512 0.25 59.913
hormone (GH; ) or placebo () in 19 malnourished hemodialysisPlacebo 59.811 6010
patients. Values are expressed as mean  SD and differences (baselineLBM kg GH 44.58.3 0.10 44.38.5
vs. 3 months) were considered significant with P  0.05.Placebo 44.87.2 44.58
TBF % GH 17.510 0.54 16.710
Placebo 17.19 16.98
Skinfold thickness mm GH 84.746 0.95 8144
mellitus type I, all other patients showed no changes inPlacebo 82.638 83.739
their fasting glucose or HbA1C levels.Abbreviations are: LBM, lean body mass; TBF, total body fat; GH, growth
hormone. Serum markers of bone formation (PICP, OC, AP)
as well as markers of bone resorption (ICTP, serum
Crosslaps) and parathyroid hormone (PTH) were eval-
parameters of bone metabolism and PMNL function uated during these three months. A significant increase
were comparable in both groups (Tables 2 and 3). in PICP from 250.1  112.6 to 478.5  235.2 g/L (P 
The IGF-I concentration increased significantly from 0.01) was observed, the increase in OC after 3 months
169.2  95.6 to 262.9  144.4 ng/mL (P  0.01) after was statistically not significant (Fig. 2). PIIINP, a non-
three months in the group receiving rhGH, whereas IGF-I bone specific marker of collagen production, rose sig-
levels showed no significant changes in the placebo nificantly during the three months of rhGH therapy (9.9
group. IGF-BP3 levels increased only slightly after three 4.9 to 14  6.5 ug/L, P  0.01). In parallel with the
months in the therapy group (P  NS; Fig. 1). markers of bone formation ICTP as a marker of bone
Serum albumin, prealbumin, transferrin, cholesterol, resorption showed a slight, but not significant increase
HDL cholesterol, cholinesterase, as well as predialytic after three months of therapy (50.3  18.5 vs. 70.0 
creatinine and blood urea nitrogen (BUN) showed no 39.5 g/L, P  NS; Fig. 2), whereas serum Crosslaps
significant changes during the three months course in the remained stable during the whole period. Since most
placebo group as well as in the therapy group (Table 2). of the patients in this study suffered from a secondary
Percent total body fat (%TBF) was slightly, but not sig- hyperparathyroidism, intact PTH was already elevated
nificantly, reduced in the GH-treated patients, whereas at baseline and rose from 198.0  139.2 to 293.4  144.8
lean body mass (LBM) remained stable in both groups. ng/mL (P  NS) in the treatment group; serum calcium
(Table 3). CRP levels were slightly elevated in both groups concentrations were comparable at baseline and after
(GH-treated group: 0.7 0.3 vs. 0.9 0.4 mg/dL, placebo three months in both groups. BMD of the lumbar spine
group: 2.2  0.9 vs. 2.6  1.2 mg/dL after 3 months) showed a significant decrease after three months in the
without correlation to the nutritional and anthropomet- treatment group (0.8  0.17 vs. 0.77  0.16 g/cm2, P 
ric parameters. Blood glucose levels rose in two patients 0.01), whereas it remained stable in the femoral neck
(receiving rhGH) with pre-existing diabetes requiring an during the whole period (Fig. 3).
At baseline phagocytic activity was lower in the groupincrease in the insulin dose of one patient with diabetes
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Fig. 2. Markers of bone formation (PICP
and OC; A, B) and markers of bone resorption
(ICTP and Crosslaps, C, D) during three
months treatment with rhGH ( ) or placebo
() in 19 malnourished hemodialysis patients.
Values are expressed as mean  SD and dif-
ferences (baseline vs. 3 months) were consid-
ered significant *P  0.05.
Fig. 4. Phagocytic activity of polymorphonuclear leukocytes (PMNL)
during 3 months of treatment with GH ( ) or placebo () in 19 mal-
nourished hemodialysis patients. Values are expressed as mean  SD
and differences (baseline vs. 3 months) were considered significant with
P  0.05.
DISCUSSION
In the past ten years, several studies have shown sig-
nificant effects of rhGH substitution therapy on body
composition (LBM, %TBF) [20–22], bone mineral den-
sity (BMD) [40, 41] and quality of life in adult patients
Fig. 3. Bone mineral density (BMD) of the lumbar spine (A) and the
with growth hormone deficiency (GHD). Immunologicalfemoral neck (B) during three months treatment with GH ( ) or pla-
cebo () in 19 malnourished hemodialysis patients. Values are ex- parameters such as natural killer-cell activity and phago-
pressed as mean  SD and differences (baseline vs. 3 months) were cytosis also have been improved by GH administration
considered significant with P  0.05.
in hypophysectomized rats [42]. In accordance with these
results in GHD patients, short- and long-term studies
with rhGH in uremic patients on chronic hemodialysisreceiving rhGH, but increased significantly after three
months (Fig. 4). In contrast, no changes were observed or continuous ambulatory peritoneal dialysis (CAPD)
have recently reported an increase in serum albuminin the placebo-treated patients. None of the other tests
of PMNL function (metabolic burst, intracellular killing, concentrations and favorable effects on several anthro-
pometric parameters and handgrip strength [23–27]. Inglucose uptake, intracellular calcium concentration) was
affected by GH (data not shown). our placebo-controlled, double-blind study, over a period
of three months no changes in nutritional and anthropo-The QoL of these patients improved after three months
of rhGH therapy as evidenced by a decrease in mean metric parameters were observed despite a significant
increase in IGF-I levels. However, rhGH therapy in-QoL AGHDA (Quality of Life Assessment of Growth
Hormone Deficiency in Adults) score of 1.4 points, duced an increase in bone turnover combined with a
decrease in BMD at the lumbar spine, an increase inwhereas the AGHDA score increased by 2.4 points in
the placebo group. NHP I showed no changes in either phagocytic activity as well as a slight improvement in
quality of life.group during the three months (Fig. 5).
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Fig. 5. Quality of life scores as measured by two self-administered questionnaires, AGHDA (A) and NHP (B) during three months of treatment
with GH or placebo.
Patients with CRF have a high incidence of protein- fold risk in mortality [5]. During the three months of
GH therapy no significant changes in the nutritional orcalorie malnutrition, and malnutrition is a strong pre-
dictor of morbidity and mortality in these individuals [5]. the anthropometric parameters were observed. In con-
trast to previously published studies in patients onMost research on anabolic hormones in catabolic condi-
tions has recently been performed with rhGH. While chronic hemodialysis, where an increase in serum albu-
min concentrations and improvement in anthropometricCRF patients have normal or even slightly elevated GH
levels and sometimes also normal IGF-I levels, resistance parameters has been described [26, 27], our patients had
markedly lower IGF-I levels before and during therapyto the anabolic actions of IGF-I in the skeletal muscle
has been described [14, 17]. Beside metabolic acidosis with rhGH. This might explain the discrepant findings
to some extent, since our patients might have exhibited[18], inflammation, and reduced nutrient intakes [19],
this resistance in the skeletal muscle has been attributed a more severe form of malnutrition and catabolism re-
sulting in more pronounced GH-resistance. This wouldto defects in cellular signaling with a defect in tyrosine
kinase activity of the IGF-I receptor and to the presence be in line with preliminary data showing that malnour-
ished patients who were severely ill and eating poorlyof circulatory inhibitors such as elevated IGFBPs. In
chronic renal failure, IGFBP-3 is usually elevated re- during GH therapy demonstrated almost no improve-
ment in nitrogen balance and albumin concentrations,sulting in reduced IGF-I bioavailability [43, 44]. There-
fore, the rationale for treating CRF patients on hemodi- despite positive effects on bone turnover [49].
Nutritional and metabolic factors affect the immunealysis with rhGH was the use of pharmacological GH
doses in an attempt to overcome GH resistance and to system of uremic patients and malnutrition is known to
impair the function of PMNL and cellular host defensepromote protein anabolism. Higher doses and/or higher
frequency of GH applications might have led to higher [50, 51], resulting in an increased incidence of infections.
Infections are the most common cause for hospitalizationIGF-I concentrations, but more likely to an increase in
side effects. and the second leading cause of death in this population
[5, 52]. Increased resting levels of intracellular calcium,The nutritional status of our patients was assessed
using several parameters including serum albumin, pre- mainly due to elevated parathyroid levels, iron overload,
zinc deficiency, malnutrition and circulating plasma in-albumin, cholesterol, HDL cholesterol, cholinesterase,
IGF-I, transferrin, predialytic creatinine, and BUN, as hibitors appear to be responsible for the impaired cellu-
lar host defense with impaired PMNL function, impairedwell as anthropometric parameters (LBM, %TBF, and
skinfold thickness) [45–48]. Among those, serum albu- phagocytosis, and decreased glucose uptake [50, 51].
There is also clinical evidence for profound defects in themin levels correlated best with morbidity and mortality,
with concentrations below 35 g/L associated with a two- specific immune defense in uremia, such as high suscepti-
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bility to viral infections, a deficient response of T-lym- GHD, we speculate that prolonged GH therapy leads
to an increase in BMD.phocytes and significantly depressed specific antibody
In conclusion, we have shown that pharmacologicalresponses. GH was able to increase the activity of cyto-
doses of rhGH increase IGF-I concentrations and inducetoxic T-lymphocytes in vitro and of natural killer cell
an increase in bone turnover with a decrease in BMDactivity in vivo, to prime macrophages for superoxide
of the lumbar spine. In addition in our malnourishedanion release and augment respiratory burst in neutro-
hemodialysis patients there was an enhanced phagocyticphils [42]. In GH-deficient patients the diminished natu-
activity of PMNLs and a slight improvement in QoL.ral killer-cell activity could be partially restored by GH.
However, no changes in nutritional and anthropometricIn the present study, GH stimulated phagocytic activity
parameters could be detected. Thus, in our severely mal-of PMNLs significantly after three months of therapy,
nourished patients, even supraphysiological doses of GHwhich could be of clinical relevance in patients with
were only partially able to overcome GH resistance.chronic renal failure requiring renal replacement ther-
apy. However, other parameters of granulocyte function
ACKNOWLEDGMENT(intracellular killing, glucose uptake, metabolic burst,
and intracellular calcium concentrations) were not af- The authors gratefully acknowledge Pharmacia for supplying GH
and placebo preparations.fected by GH. Furthermore, no significant changes in
CRP serum concentrations or the incidence of infections Reprint requests to Harald Kotzmann, M.D., Division of Endocrinol-
in both groups were observed, but clearly the number ogy and Metabolism, Department of Medicine III, University of Vienna,
Wa¨hringer Gu¨rtel 18-20, 1090 Vienna, Austria.of subjects was too small and the observation period too
E-mail: anton.luger@akh-wien.ac.at
short to expect the latter.
Bone metabolism is affected in patients on chronic
hemodialysis and leads to skeletal abnormalities known APPENDIX
as renal osteodystrophy. Theses changes can occur early Abbreviations used in this article are: BMD, bone marrow density;
in the course of renal failure and are caused by several BUN, blood urea nitrogen; CRF, chronic renal failure; CRP, C reactive
protein; DEXA, dual energy X-ray absorptiometry; GH, growth hor-pathologic mechanisms, such as phosphate retention and
mone; HDL, high density lipoprotein; HPLC, high-pressure liquid
decreased 1,25-dihydroxyvitamin D synthesis, resulting chromatography; ICTP, telopeptide; IGFBP, insulin-like growth factor
binding protein; IGF-I, insulin-like growth factor-I; IPDN, intradialyticin PTH hypersecretion and high turnover osteopathy.
parenteral nutrition; Kt/V, dialysis dose; LBM, lean body mass; NHP I,However, low turnover osteopathy, including adynamic
Nottingham Health Profile instrument; OC, osteocalcin; PCR, protein
bone disease [53, 54], also results in low BMD. Both GH catabolism rate; PICP, procollagen I carboxyterminal peptide; PIIINP,
n-terminal propeptide of type III procollagen; PMNL, polymorphonu-and IGF-I have marked effects on bone metabolism and
clear leukocyte; PTH, parathyroid hormone; QoL, quality of life; QoL-bone mineral density. GH can stimulate chondrocyte
AGHDA, Quality of Life Assessment of Growth Hormone Deficiency
growth and function and can directly or indirectly in- in Adults; rhGH, recombinant human growth hormone; RIA, radioim-
munoassay; TBF, total body fat; URR, urea reduction ratio.crease bone turnover by stimulating osteoblasts and osteo-
clasts and inducing collagen synthesis [55]. In growth hor-
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